ALX OncologyALXO
About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees: 80
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
124% more call options, than puts
Call options by funds: $427K | Put options by funds: $191K
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
7% less funds holding
Funds holding: 92 [Q3] → 86 (-6) [Q4]
8.44% less ownership
Funds ownership: 86.31% [Q3] → 77.87% (-8.44%) [Q4]
17% less capital invested
Capital invested by funds: $83.1M [Q3] → $69M (-$14.2M) [Q4]
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Stifel Bradley Canino 12% 1-year accuracy 3 / 26 met price target | 180%upside $1.50 | Hold Maintained | 7 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 190 met price target | 834%upside $5 | Buy Reiterated | 7 Mar 2025 |
Piper Sandler Christopher Raymond 26% 1-year accuracy 7 / 27 met price target | 1,581%upside $9 | Overweight Maintained | 6 Mar 2025 |
Jefferies Michael Yee 22% 1-year accuracy 2 / 9 met price target | 460%upside $3 | Buy Upgraded | 6 Mar 2025 |
Financial journalist opinion









